Alkem launches ceramide-boosting moisturizing lotion for skin barrier repair

Alkem reports posts Q1 FY26 net profit 22% higher at 664.3 Cr

Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent

Alkem reports 7.1% YoY revenue growth in Q4 FY25

Annual EBITDA margin expands by 170 basis points

Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’

Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure

IOL Chemicals and Pharmaceuticals reports Q3 FY25 revenue at Rs. 527.37 Cr

Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24

Alkem launches Kojiglo serum to manage facial hyperpigmentation

This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology

IOL Chemicals and Pharmaceuticals posts Q2 FY25 PT at Rs. 19 Cr

Total Income in Q2 FY25 stood at Rs. 532.18 crore

Alkem signs license agreement with Takeda to commercialise Vonoprazan in India

Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)

IOL Chemicals and Pharmaceuticals posts Q1 FY25 PAT at Rs. 29.7 Cr

The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24

IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24

The company recently received CEP certificate approval for Losartan Potassium by EDQM